Dr. Andrea Apolo

Yeah, and I'm glad that it was randomized because, you know, someone can argue, well, they received a systemic treatment with a checkpoint. But they did have a monotherapy checkpoint arm, and the pathologic response rate was much lower. That's right. Sorry, I could have said that, but it was 23%, so half. So it's nice to see that putting the TAR200 in the bladder intensified that.

Yeah, and I'm glad that it was randomized because, you know, someone can argue, well, they received a systemic treatment with a checkpoint. But they did have a monotherapy checkpoint arm, and the pathologic response rate was much lower. That's right. Sorry, I could have said that, but it was 23%, so half. So it's nice to see that putting the TAR200 in the bladder intensified that.

Yeah, and I'm glad that it was randomized because, you know, someone can argue, well, they received a systemic treatment with a checkpoint. But they did have a monotherapy checkpoint arm, and the pathologic response rate was much lower. That's right. Sorry, I could have said that, but it was 23%, so half. So it's nice to see that putting the TAR200 in the bladder intensified that.

the treatment effect with almost doubling of the pathologic complete response rate. So I think I'm very excited about this data. And I think that it could be something we could potentially use in the future, along with all these systemic therapies that we are now developing in the perioperative setting.

the treatment effect with almost doubling of the pathologic complete response rate. So I think I'm very excited about this data. And I think that it could be something we could potentially use in the future, along with all these systemic therapies that we are now developing in the perioperative setting.

the treatment effect with almost doubling of the pathologic complete response rate. So I think I'm very excited about this data. And I think that it could be something we could potentially use in the future, along with all these systemic therapies that we are now developing in the perioperative setting.

Yeah, and I don't understand part of the trial. I was very excited by the results. I think that it's great that there was such a great 12-month complete response rate. I think this is the best one that we have seen.

Yeah, and I don't understand part of the trial. I was very excited by the results. I think that it's great that there was such a great 12-month complete response rate. I think this is the best one that we have seen.

Yeah, and I don't understand part of the trial. I was very excited by the results. I think that it's great that there was such a great 12-month complete response rate. I think this is the best one that we have seen.

But I don't understand why the combination didn't do as well as them or the monotherapy was the one that did the best, right? So that I wasn't sure if there was some antagonism or it was just the patients. These are really small numbers, right? I mean, the combination- I think it was like 50 patients versus 85 patients in the combination arm. So these are small numbers.

But I don't understand why the combination didn't do as well as them or the monotherapy was the one that did the best, right? So that I wasn't sure if there was some antagonism or it was just the patients. These are really small numbers, right? I mean, the combination- I think it was like 50 patients versus 85 patients in the combination arm. So these are small numbers.

But I don't understand why the combination didn't do as well as them or the monotherapy was the one that did the best, right? So that I wasn't sure if there was some antagonism or it was just the patients. These are really small numbers, right? I mean, the combination- I think it was like 50 patients versus 85 patients in the combination arm. So these are small numbers.

But, you know, why is it that the monotherapy did so well in terms of the CR rate? I think it's the endpoint that is being measured. You know, if you're measuring a local endpoint. and you're giving a local therapy, the local therapy is going to shine. But why didn't it shine when it was in combination with the checkpoint?

But, you know, why is it that the monotherapy did so well in terms of the CR rate? I think it's the endpoint that is being measured. You know, if you're measuring a local endpoint. and you're giving a local therapy, the local therapy is going to shine. But why didn't it shine when it was in combination with the checkpoint?

But, you know, why is it that the monotherapy did so well in terms of the CR rate? I think it's the endpoint that is being measured. You know, if you're measuring a local endpoint. and you're giving a local therapy, the local therapy is going to shine. But why didn't it shine when it was in combination with the checkpoint?

So I don't know if this is just a little bit of noise from the... I think they were very similar in terms of the 12-month CR rate, but I would have thought that it would have been a little bit better with the combination, and it wasn't. The TAR-200 did just as well as monotherapy in terms of the 12-month CR.

So I don't know if this is just a little bit of noise from the... I think they were very similar in terms of the 12-month CR rate, but I would have thought that it would have been a little bit better with the combination, and it wasn't. The TAR-200 did just as well as monotherapy in terms of the 12-month CR.

So I don't know if this is just a little bit of noise from the... I think they were very similar in terms of the 12-month CR rate, but I would have thought that it would have been a little bit better with the combination, and it wasn't. The TAR-200 did just as well as monotherapy in terms of the 12-month CR.

So I'm excited about the antibody drug conjugates in combination with checkpoint inhibitor trials. There's three large trials, and this is, of course, because of the amazing 302 data where we saw doubling of the overall survival in patients in the first-line treatment with metastatic bladder cancer.

So I'm excited about the antibody drug conjugates in combination with checkpoint inhibitor trials. There's three large trials, and this is, of course, because of the amazing 302 data where we saw doubling of the overall survival in patients in the first-line treatment with metastatic bladder cancer.